Logo image of EVAX

EVAXION BIOTECH A/S (EVAX) Stock Fundamental Analysis

NASDAQ:EVAX - Nasdaq - US29970R3030 - ADR - Currency: USD

1.309  0 (-0.08%)

After market: 1.31 +0 (+0.08%)

Fundamental Rating

2

Overall EVAX gets a fundamental rating of 2 out of 10. We evaluated EVAX against 568 industry peers in the Biotechnology industry. EVAX may be in some trouble as it scores bad on both profitability and health. EVAX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EVAX had positive earnings in the past year.
EVAX had a negative operating cash flow in the past year.
EVAX had negative earnings in each of the past 5 years.
EVAX had a negative operating cash flow in each of the past 5 years.
EVAX Yearly Net Income VS EBIT VS OCF VS FCFEVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

EVAX has a Return On Assets of -84.65%. This is in the lower half of the industry: EVAX underperforms 70.95% of its industry peers.
Industry RankSector Rank
ROA -84.65%
ROE N/A
ROIC N/A
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVAX Yearly ROA, ROE, ROICEVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EVAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVAX Yearly Profit, Operating, Gross MarginsEVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

3

2. Health

2.1 Basic Checks

EVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EVAX has more shares outstanding
EVAX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, EVAX has an improved debt to assets ratio.
EVAX Yearly Shares OutstandingEVAX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EVAX Yearly Total Debt VS Total AssetsEVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

EVAX has an Altman-Z score of -4.22. This is a bad value and indicates that EVAX is not financially healthy and even has some risk of bankruptcy.
EVAX has a Altman-Z score (-4.22) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.22
ROIC/WACCN/A
WACC4.97%
EVAX Yearly LT Debt VS Equity VS FCFEVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

EVAX has a Current Ratio of 2.01. This indicates that EVAX is financially healthy and has no problem in meeting its short term obligations.
EVAX's Current ratio of 2.01 is on the low side compared to the rest of the industry. EVAX is outperformed by 74.82% of its industry peers.
A Quick Ratio of 2.01 indicates that EVAX has no problem at all paying its short term obligations.
EVAX has a Quick ratio of 2.01. This is in the lower half of the industry: EVAX underperforms 73.42% of its industry peers.
Industry RankSector Rank
Current Ratio 2.01
Quick Ratio 2.01
EVAX Yearly Current Assets VS Current LiabilitesEVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 107.68% over the past year.
Looking at the last year, EVAX shows a very strong growth in Revenue. The Revenue has grown by 4480.82%.
EPS 1Y (TTM)107.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.63%
Revenue 1Y (TTM)4480.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

EVAX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -31.97% yearly.
Based on estimates for the next years, EVAX will show a very strong growth in Revenue. The Revenue will grow by 61.85% on average per year.
EPS Next Y-456.19%
EPS Next 2Y5.69%
EPS Next 3Y-56.74%
EPS Next 5Y-31.97%
Revenue Next Year1.47%
Revenue Next 2Y42.56%
Revenue Next 3Y59.75%
Revenue Next 5Y61.85%

3.3 Evolution

EVAX Yearly Revenue VS EstimatesEVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M
EVAX Yearly EPS VS EstimatesEVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2031 2032 0 -20 -40

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 2.08 indicates a rather cheap valuation of EVAX.
Compared to the rest of the industry, the Price/Earnings ratio of EVAX indicates a rather cheap valuation: EVAX is cheaper than 99.30% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of EVAX to the average of the S&P500 Index (28.29), we can say EVAX is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for EVAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 2.08
Fwd PE N/A
EVAX Price Earnings VS Forward Price EarningsEVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVAX Per share dataEVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

EVAX's earnings are expected to decrease with -56.74% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.69%
EPS Next 3Y-56.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EVAX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVAXION BIOTECH A/S

NASDAQ:EVAX (4/17/2025, 8:15:54 PM)

After market: 1.31 +0 (+0.08%)

1.309

0 (-0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-01 2025-04-01/bmo
Earnings (Next)05-26 2025-05-26
Inst Owners2.61%
Inst Owner Change0%
Ins Owners0.68%
Ins Owner ChangeN/A
Market Cap8.27M
Analysts82.5
Price Target47.37 (3518.79%)
Short Float %1.47%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.28%
Min EPS beat(2)86.32%
Max EPS beat(2)98.23%
EPS beat(4)4
Avg EPS beat(4)101.85%
Min EPS beat(4)69.83%
Max EPS beat(4)152.99%
EPS beat(8)7
Avg EPS beat(8)51.25%
EPS beat(12)10
Avg EPS beat(12)39.44%
EPS beat(16)12
Avg EPS beat(16)29.3%
Revenue beat(2)1
Avg Revenue beat(2)42.12%
Min Revenue beat(2)-92.79%
Max Revenue beat(2)177.04%
Revenue beat(4)3
Avg Revenue beat(4)77.43%
Min Revenue beat(4)-92.79%
Max Revenue beat(4)190.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)328%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1081.82%
EPS NY rev (1m)0%
EPS NY rev (3m)-74.6%
Revenue NQ rev (1m)-50%
Revenue NQ rev (3m)-4.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)43.92%
Valuation
Industry RankSector Rank
PE 2.08
Fwd PE N/A
P/S 2.47
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.63
EY48.13%
EPS(NY)-2.24
Fwd EYN/A
FCF(TTM)-2.05
FCFYN/A
OCF(TTM)-2.05
OCFYN/A
SpS0.53
BVpS-0.26
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.65%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.01
Quick Ratio 2.01
Altman-Z -4.22
F-Score5
WACC4.97%
ROIC/WACCN/A
Cap/Depr(3y)21.76%
Cap/Depr(5y)127.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)107.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.63%
EPS Next Y-456.19%
EPS Next 2Y5.69%
EPS Next 3Y-56.74%
EPS Next 5Y-31.97%
Revenue 1Y (TTM)4480.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1.47%
Revenue Next 2Y42.56%
Revenue Next 3Y59.75%
Revenue Next 5Y61.85%
EBIT growth 1Y33.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.86%
OCF growth 3YN/A
OCF growth 5YN/A